Antiretroviral Therapy-Associated Acute Motor and Sensory Axonal Neuropathy

Kimberly N. Capers a  Sinan Turnacioglu a
Robert T. Leshner a  John R. Crawford b

aDepartment of Neurology, Children’s National Medical Center, The George Washington University School of Medicine, Washington, D.C., and bDepartment of Neurosciences and Pediatrics, University of California San Diego, San Diego, Calif., USA

Key Words
Acute axonal neuropathy · Guillain-Barré syndrome · HIV infection · Highly active antiretroviral therapy

Abstract
Guillain-Barré syndrome (GBS) has been reported in HIV-infected patients in association with the immune reconstitution syndrome whose symptoms can be mimicked by highly active antiretroviral therapy (HAART)-mediated mitochondrial toxicity. We report a case of a 17-year-old, HIV-infected patient on HAART with a normal CD4 count and undetectable viral load, presenting with acute lower extremity weakness associated with lactatemia. Electromyography/nerve conduction studies revealed absent sensory potentials and decreased compound muscle action potentials, consistent with a diagnosis of acute motor and sensory axonal neuropathy. Lactatemia resolved following cessation of HAART; however, neurological deficits minimally improved over several months in spite of immune modulatory therapy. This case highlights the potential association between HAART, mitochondrial toxicity and acute axonal neuropathies in HIV-infected patients, distinct from the immune reconstitution syndrome.

Introduction
Guillain-Barré syndrome (GBS) is an acute peripheral neuropathy classified into at least four subgroups by electrodiagnostic criteria, pathology, and anti-ganglioside antibody profiles [1]. GBS has been reported in patients with primary HIV infection, although this is not commonly observed [2]. In HIV-infected patients, GBS has been reported in association with the immune reconstitution syndrome, whereby there is a re-emergence of previously anergic lymphocytes upon viral suppression with highly active antiretroviral therapy (HAART) [3–7]. Nucleoside analogue reverse transcriptase
inhibitors (NRTIs), a key component of HAART, have been related to GBS in HIV-infected individuals in association with the immune reconstitution syndrome [8–10]. Bristol-Myers Squibb reported 22 cases of GBS associated with stavudine therapy, each with lactatemia, resulting in 7 deaths [10]. We report a case of an HIV-infected adolescent presenting with subacute weakness and lactatemia, diagnosed with acute motor and sensory axonal neuropathy (AMSAN) following long-term HAART therapy, distinct from the immune reconstitution syndrome.

Case Report

A 17-year-old female with HIV secondary to a blood transfusion during infancy presented after a fall at home. The patient complained of generalized weakness for 4–5 days prior to admission that resulted in a buttock abscess. Pertinent past medical history includes HIV-associated pulmonary hypertension, cardiomyopathy, sensorineural hearing loss, major depressive disorder, and complex partial epilepsy. Her antiretroviral regimen included stavudine, abacavir, ritonavir, and lopinavir that were administered by a caretaker daily for several years. She underwent frequent follow-up assessments in the HIV clinic, with routine periodic viral load and CD4 lymphocyte monitoring.

On neurological examination, the patient was alert and oriented to person, time and place, with a depressed affect. Cranial nerves 1–12 were intact. There was marked pitting edema of the hands and feet, with greater distal than proximal weakness of the upper (3/5) and lower extremities (2/5) bilaterally. Patellar and Achilles reflexes were 1+ bilaterally. Sensation to pain and temperature and joint position sense were normal. The patient was unable to ambulate independently due to the profound weakness. She received normal saline intravenously for tachycardia, and broad-spectrum antibiotics were initiated for suspected sepsis secondary to her buttock abscess. Laboratory tests revealed a complete blood count of 19.2 with 41 bands, and an elevated serum lactate level (13.5 mmol/l). The patient had a CD4 count of 392 cells/mm³ and an undetectable viral load (table 1). Results from a lumbar puncture were within normal limits for white blood cells, red blood cells, glucose, and protein levels. Cerebrospinal fluid studies were negative for herpesvirus 1/2, Epstein-Barr virus, cytomegalovirus, and Treponema pallidum. Magnetic resonance imaging of the brain and spine with and without gadolinium showed normal findings. All antiretroviral medications were discontinued due to the lactatemia, concerning for possible mitochondrial toxicity. Electromyogram (EMG) and nerve conduction studies (NCS) revealed numerous abnormalities, leading to the final diagnosis of AMSAN (table 2). First, there were absent sensory nerve action potentials in the medial, ulnar, sural, and superficial peroneal nerves. Second, very low compound muscle action potentials (CMAPs) were recorded at the median, peroneal, and tibial nerves, with absent CMAPs of the ulnar nerve. F wave studies showed prolonged distal latencies, with relative sparing of nerve conduction velocities. Finally, EMG elicited positive sharp waves and fibrillations. The constellation of EMG and NCS findings were consistent with a diagnosis of AMSAN. The patient was empirically treated with intravenous immunoglobulin (0.4 mg/kg/day) for 5 days but failed to show significant improvement in her distal extremity weakness in spite of a normalized lactate level.

Three months after discharge, the patient had minor improvements in strength of her distal upper extremities (4/5) when compared to distal lower extremities (2/5), and was still unable to ambulate independently.

Discussion

The classical GBS variants follow an infectious prodrome, resulting in an augmented immune response which cross-reacts with axolemmal or Schwann cell antigens, leading to peripheral nerve damage via molecular mimicry [1]. GBS may occur in HIV-infected patients at the time of seroconversion or, more commonly, in the setting of the immune reconstitution syndrome [3–5, 7]. The immune recovery phase, evidenced by an increase in the CD4 lymphocyte count and a decrease in the HIV viral load, is presumably
responsible for the neuroimmune-mediated attack. While other cases of GBS associated with lactic acidosis related to HAART have been reported [8, 11], this is the first case of GBS, AMSAN in particular, occurring in the absence of the immune reconstitution syndrome. Although impossible to prove conclusively, the most likely mechanism of AMSAN in our patient was HAART-associated mitochondrial toxicity. This is evidenced by an acute lactatemia, in the absence of any other etiology, which resolved upon cessation of antiretroviral therapies. The confounding buttock abscess observed on examination would be another potential source of lactatemia; however, the abrupt cessation of HAART showed immediate and sustained decrease in the serum lactate level, consistent with a hypothesis of a HAART-related phenomenon. Given the patient's tremendous amount of comorbidities, including cardiomyopathy, sensorineural hearing loss, and pulmonary hypertension, an underlying previous undiagnosed mitochondrial cytopathy could also explain the patient’s symptomatology. However, mitochondrial DNA testing was performed at admission which was unrevealing. A pre-existing or acquired mitochondrial cytopathy cannot be completely ruled out since the entire nuclear and mitochondrial genomes were not sequenced. Given the numerous reports of HAART-related mitochondrial toxicity in HIV-infected patients, we believe a subset of patients may have HIV- or drug-induced mitochondrial toxicity as opposed to an underlying mitochondrial cytopathy prior to diagnosis.

HAART-related mitochondrial toxicity has been associated with lactatemia and death, particularly in the case of stavudine [10]. Chronic stavudine use, in addition to lactatemia, has been associated with Miller Fisher syndrome in one case report [8]. It is hypothesized that NRTIs, in particular zidovudine, induce myotoxicity via oxidative stress, inhibition of the mitochondrial machinery, and L-carnitine deficiency [9]. NRTIs may alter the function of the mitochondrial enzyme DNA polymerase gamma, leading to dysfunction or depletion in addition to HIV-induced mitochondrial toxicity [12]. Stavudine has been hypothesized to mimic GBS via the inhibition of the mitochondrial polymerase gamma enzyme [13]. Other HAARTs are likely to affect the mitochondrial machinery via similar mechanisms, as opposed to altering the nuclear to mitochondrial DNA ratios, which has been shown to be an ineffective marker of HAART-associated mitochondrial toxicity [14].

One possible treatment of HAART-associated GBS is stabilization of the mitochondria via carnitine therapy. Unfortunately, in our patient, total and free carnitine levels were not measured and vitamin/cofactor therapies were not utilized. These would have been reasonable therapeutic options as the patient responded only minimally to intravenous immunoglobulin treatment, supporting a role of therapy-induced mitochondrial toxicity in addition to an immune-mediated pathophysiology. To further support a neuroimmune mechanism of the disease, IgG anti-ganglioside antibodies to GM1, GM1b, and GD1a may have been useful in the disease classification. Plasmapheresis, a common therapeutic modality for AMSAN, was not attempted in our patient because of her higher procedural risk secondary to severe HIV-related chronic pulmonary hypertension and cardiomyopathy.

Conclusion

Clinicians should be aware that GBS variants can occur in both adult and pediatric HIV patients on chronic HAART in the absence of an immune reconstitution syndrome.
Both mitochondrial toxicity (evidenced by elevated serum lactate) and neuroimmune mechanisms may play a role in disease pathogenesis.

**Table 1.** Laboratory values

|                      | Results | Normal values |
|----------------------|---------|---------------|
| **Hematology**       |         |               |
| WBC, K/mcl           | 19.2    | 4.19–9.43     |
| Bands, %             | 41      | 0–1           |
| Segs, %              | 30      | 45–76         |
| Lymphocytes, %       | 15      | 14–41         |
| Monocytes, %         | 9       | 4–8           |
| Hemoglobin, g/dl     | 10.1    | 10.8–13.3     |
| Platelets, K/mcl     | 309     | 194–345       |
| CD4, cells/mm³       | 392     | 500–1,500     |
| HIV viral load, copies/ml | 0 | 0 |
| **Chemistry**        |         |               |
| Na, mmol/l           | 131     | 133–143       |
| K+, mmol/l           | 3.9     | 3.3–4.7       |
| Cl–, mmol/l          | 91      | 97–107        |
| Blood urea nitrogen, mg/dl | 4 | 7–21 |
| Creatinine, mg/dl    | 0.5     | 0.5–1.1       |
| Albumin, g/dl        | 3.6     | 3.8–5.6       |
| Alkaline phosphatase, u/l | 94 | 82–169 |
| Direct bilirubin, mg/dl | 2.74 | <0.4 |
| Total bilirubin, mg/dl | 3.8  | <0.8 |
| Aspartate aminotransferase, u/l | 46 | 0–26 |
| Alamine aminotransferase, u/l | 14 | 19–49 |
| Lactate, mmol/l      | 13.5    | 1–2.4         |
| Pyruvate, mg/dl      | 1.67    | 0.3–1.5       |
| **Coagulation**      |         |               |
| PT, s                | 16.5    | 11.5–13.8     |
| PTT, s               | 30      | 22.3–34.4     |
| INR                  | 1.4     | 0.8–1.1       |
| **Cerebrospinal fluid** |   |               |
| WBC, /μl             | 1       | 0–6           |
| RBC, /μl             | 1       | 0             |
| Protein, mg/dl       | 31      | 15–45         |
| Glucose, mg/dl       | 93      | 41–84         |
| CMV PCR              | negative|               |
| EBV                  | negative|               |
| HSV-1, HSV-2         | negative|               |
| VDRL                 | non reactive|             |
| **Other**            |         |               |
| Valproic acid, mg/μl | 56      | 50–100        |
| Ammonia, μmol/l      | 24      | 29–54         |
| Thyroid-stimulating hormone, μu/ml | 3.40 | 0.51–4.91 |
| B12, pg/ml           | 1,892   | 210–911       |
| Free T4, ng/dl       | 1.94    | 1.1–1.6       |
| RPR                  | NR      | NR            |
### Table 2. Summary of electromyogram and nerve conduction studies

| Nerve, location | Amplitude mV | Distance cm | Latency ms | Conduction velocity, m/s |
|----------------|--------------|-------------|------------|--------------------------|
| **Motor nerve conduction studies** | | | | |
| Ulnar, wrist | 0 | 7 | | |
| Ulnar, below elbow | 0 | 20 | | |
| Ulnar, above elbow | 0 | 10 | | |
| Median, wrist | 0.1 | 6 | 4.40 | |
| Median, elbow | 0.1 | 20 | 7.90 | 57.1 |
| Peroneal, ankle | 0.3 | 6 | 5.00 | |
| Peroneal, fibula | 0.4 | 30 | 13.10 | 37.0 |
| Peroneal, knee | 0.2 | 8 | 15.45 | 34.0 |
| Tibial, knee | 0.3 | 30 | 14.90 | |
| **Sensory nerve conduction studies** | | | | |
| Median, wrist | 13 | None | | |
| Ulnar, wrist | 11 | None | | |
| Sural, calf | 12 | None | | |
| Superior peroneal, lateral | 12 | None | | |
| Medial plantar, sole | 14 | None | | |

| Nerve | Spontaneous MUAP | Recruitment |
|-------|-----------------|-------------|
| IA    | FIB | PSW | FASC | HFD | AMP | DUR | PPP |
| Tibialis anterior | 3+ | 3+ | 3+ | 0 | 0 | 0 | 0 | None |
| Gastrocnemius | 3+ | 3+ | 3+ | 0 | 0 | 0 | 0 | None |
| Vastus lateralis | 3+ | 3+ | 3+ | 0 | 0 | 0 | 0 | None |
| Biceps | 1+ | 1+ | 1+ | 0 | 0 | 0 | 1+ | Reduced |
| Deltoid | 1+ | 0 | 0 | 0 | 0 | 0 | 0 | Reduced |
| First dorsal interosseus | 3+ | 3+ | 2+ | 0 | 0 | 0 | 0 | None |

MUAP = Motor unit action potential; IA = insertional activity; FIB = fibrillations; PSW = positive sharp waves; FASC = fasciculations; HFD = high-frequency discharges; AMP = amplitude; DUR = duration; PPP = polyphasic potentials.

### References

1. Hughes RA, Cornblath DR: Guillain-Barré syndrome. Lancet 2005;366:1653–1666.
2. Hagberg L, Dahlqvist RE, Svennerholm L, Alestig K, Norkrans G: Guillain-Barré syndrome as an early manifestation of HIV central nervous system infection. Scand J Infect Dis 1986;18:591–592.
3. Hirsch HH, Kaufmann G, Sendi P, Battegay M: Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004;38:1159–1166.
4. Makela P, Howe L, Glover S, Ferguson I, Pinto A, Gompels M: Recurrent Guillain-Barre syndrome as a complication of immune reconstitution in HIV. J Infect Dis 2004;189:147–149.
5. Piliero PJ, Fish DG, Preston S, et al: Guillain-Barré syndrome associated with immune reconstitution. Clin Infect Dis 2003;36:e111–114.
6. Puththanakit T, Oberdoerfer P, Akrathum N, Wannarat P, Sirisanthana T, Sirisanthana V: Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected thai children. Pediatr Infect Dis J 2006;25:53–58.
Teo EC, Azwra A, Jones RL, Gazzard BG, Nelson M: Guillain-Barre syndrome following immune reconstitution after antiretroviral therapy for primary HIV infection. J HIV Ther 2007;12:62–63.

Shah SS, Rodriguez T, McGowan JP: Miller Fisher variant of Guillain-Barré syndrome associated with lactic acidosis and stavudine therapy. Clin Infect Dis 2003;36:e131–e133.

Wooltorton E: HIV drug stavudine (Zerit, d4T) and symptoms mimicking Guillain-Barré syndrome. Cmaj 2002;166:1067.

Stavudine, Zerit Bristol-Myers Squibb, Product information 2006.

Rosso R, Di Biagio A, Ferrazin A, Bassetti M, Ciravegna BW, Bassetti D: Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection. Pediatr Infect Dis J 2003;22:668–670.

Scruggs ER, Dirks Naylor AJ: Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy. Pharmacology 2008;82:83–88.

White AJ: Mitochondrial toxicity and HIV therapy. Sex Transm Infect 2001;77:158–173.

Montaner JS, Cote HC, Harris M, et al: Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy. J Acquir Immune Defic Syndr 2003;34(suppl1):S85–S90.